Increased demand and manufacturing delays are causing the nationwide shortage.
pharmacist looking at orange Rx prescription bottle

The Food and Drug Administration (FDA) has confirmed that the current nationwide Adderall shortage could last until 2023.

The drug, which helps with attention deficit hyperactivity disorder (ADHD), has been facing order delays for some time now. Pharmacies have reported difficulties filling prescriptions for the stimulant for more than two months.

Both an increase in demand for the medication and manufacturing delays have caused the shortage. On the manufacturing side, a summer labor shortage on a packaging line set companies like Teva Pharmaceuticals back. Though that issue has since been resolved, inventory recovery can take months to catch up. 

In regard to the increased demand, there has been a significant increase in ADHD diagnoses in both children and adults. The uptick also coincides with the Covid-19 lockdown and overall increased awareness about ADHD. Adderall prescriptions themselves went up by 10.4% from 2020 to 2021 and spiked to 41.4 million prescriptions dispensed. 

While interrupting Adderall usage is not technically life-threatening, it can cause symptoms to return and can be extremely distressing. The FDA and experts advise those affected to consult with their doctors to find the best intermittent treatment.

Navigate the News Better

Take a five-minute trip through the news that matters most to travelers with our daily newsletter.

Related Stories

Join The Navigator

Navigate the news better.

This post contains references to products from one or more of our advertisers. We may receive compensation when you click on links to those products. Terms apply to the offers listed on this page. For an explanation of our Advertising Policy, visit this page.